Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

First FDA Generic Approval Granted For Hydrocortisone Butyrate Lotion 0.1%

By Teligent, Inc. | November 27, 2017

Teligent, Inc. announces first FDA generic approval of Hydrocortisone Butyrate Lotion 0.1%.

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced it has received approval of the company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Butyrate Lotion 0.1%. It is Teligent’s ninth approval for 2017, and its 19th approval from its internally developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health data from September 2017, the total addressable market for this product is approximately $17.0 million.

“We submitted this ANDA on August 31, 2016, pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act),” Jason Grenfell-Gardner, president and CEO of the company, said. “As we were the first ANDA applicant to submit an ANDA with a paragraph IV certification for Hydrocortisone Butyrate Lotion, 0.1%, with this approval Teligent is eligible for 180 days of generic drug exclusivity for Hydrocortisone Butyrate Lotion, 0.1%.  We expect to launch this product in the first quarter of 2018.”

Grenfell-Gardner aded that the company now has 24 topical generic pharmaceutical products and four injectable products in its U.S. portfolio.

(Source: Teligent Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE